Principal Financial Group Inc Allakos Inc. Transaction History

Principal Financial Group Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 09, 2022	SELL	$8.55 - $111.89 $153,463 - $2.01 Million	-17,949 Closed	0 $0
Q3 2021 Nov 09, 2021	BUY	$76.53 - $110.43 $4,362 - $6,294	57 Added 0.32%	17,949 $1.9 Million
Q2 2021 Aug 10, 2021	BUY	$85.37 - $114.1 $106,968 - $142,967	1,253 Added 7.53%	17,892 $1.53 Million
Q1 2021 May 10, 2021	SELL	$109.73 - $153.66 $9,436 - $13,214	-86 Reduced 0.51%	16,639 $1.91 Million
Q4 2020 Feb 08, 2021	BUY	$79.58 - $152.45 $217,890 - $417,408	2,738 Added 19.58%	16,725 $2.34 Million
Q3 2020 Nov 06, 2020	SELL	$66.43 - $90.99 $38,064 - $52,137	-573 Reduced 3.94%	13,987 $1.14 Million
Q2 2020 Aug 05, 2020	BUY	$44.04 - $80.69 $312,463 - $572,495	7,095 Added 95.04%	14,560 $1.05 Million
Q1 2020 May 12, 2020	SELL	$44.49 - $93.39 $96,187 - $201,909	-2,162 Reduced 22.46%	7,465 $332,000
Q4 2019 Feb 05, 2020	BUY	$66.49 - $137.73 $37,034 - $76,715	557 Added 6.14%	9,627 $918,000
Q3 2019 Nov 13, 2019	BUY	$31.0 - $89.73 $80,600 - $233,298	2,600 Added 40.19%	9,070 $713,000
Q2 2019 Aug 12, 2019	BUY	$36.0 - $44.73 $232,920 - $289,403	6,470 New	6,470 $280,000

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $89.8M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.